-+ 0.00%
-+ 0.00%
-+ 0.00%

Krystal Biotech To Report Interim Clinical Study Update From CORAL-1 Phase 1 Trial Of KB407 In Participants With Cystic Fibrosis

Benzinga·01/07/2026 21:07:29
Listen to the news

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company's multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407.